Novo Nordisk (NVO 2.98%) stock investors are eagerly awaiting the potential launch of its weight loss treatment in oral form.
*Stock prices used were the afternoon prices of Sept. 25, 2025. The video was published on Sept. 27, 2025.
Political pressure on Big Pharma is one reason why the industry is underperforming in 2025.
Novo Nordisk (NVO 2.98%) stock investors are eagerly awaiting the potential launch of its weight loss treatment in oral form.
*Stock prices used were the afternoon prices of Sept. 25, 2025. The video was published on Sept. 27, 2025.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.